ABUS · Arbutus Biopharma Corp · Executive Compensation
$4.02
-0.05 (-1.23%)
At close · Nov 20
Return incl. dividend (before tax)
Q3 2024 earnings call transcript
Market Cap
$616.24M
Shares
153.29M
Volume · Nov 20
2.99M
Avg daily vol (3M)
5.19M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael J. McElhaugh | Former Interim President and Chief Executive Officer | $3,578,150 |
| Tuan Nguyen | Chief Financial Officer | $2,416,995 |
| David C. Hastings | Former Chief Financial Officer | $2,218,362 |
| Lindsay Androski | President and Chief Executive Officer | $1,369,013 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael J. McElhaugh | Former Interim President and Chief Executive Officer | $2,110,083 |
| David C. Hastings | Former Chief Financial Officer | $1,825,846 |
| Michael Sofia | Former Chief Scientific Officer | $1,820,054 |
| Karen Sims | M.D., Ph.D. Former Chief Medical Officer | $1,697,375 |
| Tuan Nguyen | Chief Financial Officer | — |
| Lindsay Androski | President and Chief Executive Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| William Collier | Former President and Chief Executive Officer | $3,385,984 |
| Elizabeth Howard | Former Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | $1,842,723 |
| Michael J. McElhaugh | Former Interim President and Chief Executive Officer | $1,620,485 |
| Michael Sofia | Former Chief Scientific Officer | $1,614,688 |
| David C. Hastings | Former Chief Financial Officer | $1,556,806 |
| Karen Sims | M.D., Ph.D. Former Chief Medical Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| William Collier | Former President and Chief Executive Officer | $2,645,657 |
| Michael J. McElhaugh | Current Interim President and Chief Executive Officer | $1,315,235 |
| Michael Sofia | Chief Scientific Officer | $1,248,210 |
| Elizabeth Howard | Former Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| William Collier | President and Chief Executive Officer | $3,215,289 |
| Michael Sofia | Chief Scientific Officer | $1,609,160 |
| David C. Hastings | Chief Financial Officer | $1,456,535 |
| Michael J. McElhaugh | COO | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| William Collier | President and Chief Executive Officer | $2,728,324 |
| Michael Sofia | Chief Scientific Officer | $1,243,203 |
| Michael J. McElhaugh | — | $1,087,791 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mark J. Murray | Former President and Chief Executive Officer | $3,780,430 |
| William Collier | President and Chief Executive Officer | $2,334,185 |
| Michael Sofia | Chief Scientific Officer | $1,051,388 |
| David C. Hastings | Chief Financial Officer | $1,010,250 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Mark J. Murray | Former President and Chief Executive Officer | $2,527,885 |
| David C. Hastings | Chief Financial Officer | $1,452,867 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Roger Sawhney, MD | director | Appointed | 2026-05-27 |
| Joseph Bishop | director | Appointed | 2026-05-27 |
| Matthew Gline | director | Appointed | 2026-05-27 |
| Robert Alan Beardsley | director | Appointed | 2026-05-27 |
| Lindsay Androski, JD, MBA, CFA | director | Appointed | 2026-05-27 |
| Roger Sawhney | Board | Appointed | 2025-08-06 |
|
Anuj Hasija
“The resignation of Mr. Hasija is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2025-08-06 |
| David Hastings | Chief Financial Officer | Terminated | 2025-04-03 |
|
Michael J. McElhaugh
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Interim President and Chief Executive Officer | Resigned | 2025-02-25 |
| Lindsay Androski | chairperson of the Board | Appointed | 2025-02-25 |
| Lindsay Androski | President and Chief Executive Officer | Appointed | 2025-02-25 |
| Anuj Hasija | member of the Board | Appointed | 2025-02-25 |
| Matthew Gline | member of the Board | Appointed | 2025-02-25 |
| Robert Alan Beardsley | member of the Board | Appointed | 2025-02-25 |
| Joseph Bishop | member of the Board | Appointed | 2025-02-25 |
| Lindsay Androski | member of the Board | Appointed | 2025-02-25 |
|
Melissa V. Rewolinski, Ph.D.
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2025-02-25 |
|
Keith Manchester, M.D.
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2025-02-25 |
|
James Meyers
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2025-02-25 |
|
Richard C. Henriques
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2025-02-25 |
|
Daniel Burgess
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2025-02-25 |
|
Michael J. McElhaugh
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2025-02-25 |
|
Frank Torti, M.D.
“None of the departures from the Board described herein are the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
chairperson of the Board | Resigned | 2025-02-25 |
| Michael J. Sofia | Chief Scientific Officer | Retired | 2024-10-11 |
| Dr. Michael Sofia | Chief Scientific Officer | Retired | 2024-05-02 |
Leadership
- Lindsay Androski CEO, Chairman, Board Member
- Mark J. Murray CEO
- Tuan Nguyen CFO
- Michael J. McElhaugh COO
- Mike McElhaugh COO
- J. Christopher Naftzger General Counsel
- Anuj Hasija Board Member
- Eric Venker, M.D., Pharm.D. Board Member
- Frank Torti, M.D. Board Member
- Joseph Bishop Board Member
- Lindsay Androski, JD, MBA, CFA Board Member
- Matthew Gline Board Member
- Robert Alan Beardsley Board Member
- Roger Sawhney Board Member
- Roger Sawhney, MD Board Member
- Tram Tran, M.D. Board Member
Key facts
CIK
1447028
CUSIP
03879J100
13F (30d)
221 filings
200 filers
Visit website
Investor relations